MustGrow Biologics (CSE: MGRO) this morning announced it will be conducting a small financing. The firm will look to raise $2.0 million via a non-brokered financing.
Under the terms of the financing, the company is selling units at a price of $2.60 per each. Each unit contains one common share and one full warrant, with each warrant priced at $4.00 per common share. Warrants are valid for a period of two years from the date of issuance.
Funds from the financing are to be used for the continued development of its pipeline assets, as well as for working capital and general corporate purposes.
The financing is expected to close September 28.
The news follows a major announcement made by the company last month, wherein it has entered into an exclusive evaluation and option agreement with that of Sumitomo Corporation.
MustGrow Biologics last traded at $3.00 on the CSE.
FULL DISCLOSURE: MustGrow Biologics Corp is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover MustGrow Biologics Corp on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.